Participants were postmenopausal women with a median age of 54 (48–71) y for VMI, FSH, and estradiol and 55 (49–74) y for ET, without a diagnosis of a chronic disease, except for 1 trial involving participants with a history of breast cancer and another with insulin resistance. Here, BRD2 is linked to breast carcinoma.